Company (location)

Product

Description

Indication

Status

Date

Cancer

Aptevo Therapeutics Inc. (Seattle)

Otlertuzumab

Monospecific antibody targeting CD37

Peripheral T-cell lymphoma

Commenced patient dosing in a phase II study

1/9/18

Avelas Biosciences Inc. (San Diego)

ABV-620

IV protease-activatable flourescent peptide

Primary, nonrecurrent breast cancer

Completed period 1 patient enrollment in its phase II trial

1/5/18

Bergenbio ASA (Bergen, Norway)

BGB324

Bemcentinib

Advanced non-small-cell lung cancer

The first efficacy endpoint was met in its phase II BGBC004 trial in patients who have progressed on an approved EGFR inhibitor; it plus Tarceva produced an overall disease control rate of 33% in nine patients who completed at least one cycle of treatment

1/10/18

Bergenbio ASA (Bergen, Norway)

BGB-324

Bemcentinib

Triple-negative breast cancer and non-small cell lung cancer

Interim safety data from three phase II trials in combination with Keytruda, as well as an AXL immunohistochemistry method, showed to clearly detect the presence of AXL on tumor and immune cells in patient samples

1/30/18

Bergenbio ASA (Bergen, Norway)

BGB-324

Bemcentinib

Acute myeloid leukemia

Analyses from a phase II trial showed a clear immunomodulatory effect as a result of selective AXL inhibition, as evidenced by increased immune activity characterized by diversification of patients' T-cell receptor repertoire

1/30/18

Biolinerx Ltd. (Tel Aviv, Israel)

BL-8040

Short peptide designed to function as a high-affinity antagonist for CXCR4

Metastatic pancreatic cancer

Phase IIa COMBAT data showed it increases infiltration of T cells into the tumor in patients with metastatic pancreatic cancer; it was safe, well tolerated and induced an increase in the number of total immune cells in the peripheral blood while the frequency of peripheral blood regulatory T cells was decreased; analysis of available biopsies (n= 7) showed infiltration of various types of effector T cells into the tumor periphery and tumor microenvironment

1/18/18

Biomarck Pharmaceuticals Ltd. (Durham, N.C.)

BIO-11006

Inhibitor of MARCKS protein

Non-small-cell lung cancer

Started a phase II trial

1/24/18

Bio-Path Holdings Inc. (Houston)

Prexigebersen

RNAi nanoparticle

Accelerated and blast phase chronic myeloid leukemia

Initiated a phase IIa study

1/3/18

Bridgebio Pharma Inc. (Palo Alto)

BGJ-398

Infigratinib

Cholangiocarcinoma containing FGFR2 fusions

Early phase II results found meaningful activity

1/31/18

Bristol-Myers Squibb Co. (New York)

Opdivo and Yervoy

Nivolumab and ipilimumab

DNA mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer

Phase II CheckMate-142 data showed the combination produced an objective response rate of 55%; with 13.4 months of follow-up, 94% of the responses were still ongoing; the overall survival (OS) rate at one year was 85%, while the median OS hadn't been reached yet

1/23/18

Celgene Corp. (Summit, N.J.)

Abraxane

Nab-paclitaxel

Locally advanced pancreatic cancer

Phase II LAPACT data showed it plus gemcitabine produced a median time to treatment failure of 8.8 months, which exceeded the protocol-specified target of 6.6 months; the overall response rate was 32% with a median progression-free survival of 10.8 months; the estimated one-year overall survival was 72%

1/23/18

Cellectar Biosciences Inc. (Madison, Wis.)

CLR-131

Radiotherapeutic phospholipid-drug conjugate

Relapsed or refractory B-cell hematologic cancers

Enrolled the first patient in the diffuse large B-cell lymphoma (DLBCL) cohort of its phase II trial

1/30/18

Iovance Biotherapeutics Inc. (San Carlos, Calif.)

LN-145

Autologous tumor infiltrating lymphocytes

Recurrent and/or metastatic squamous cell carcinoma of the head and neck

Preliminary phase II C-145-03 data showed it produced a reduction of tumor size of at least 30% in three of eight patients

1/26/18

Iovance Biotherapeutics Inc. (San Carlos, Calif.)

LN-145

Autologous tumor infiltrating lymphocytes

Recurrent, metastatic or persistent cervical carcinoma

Preliminary phase II C-145-04 data showed one partial response and one patient with stable disease among two currently evaluable patients

1/26/18

Merck & Co. Inc. (Kenilworth, N.J.)

Keytruda

Pembrolizumab

Advanced hepatocellular carcinoma

Results of the phase II KEYNOTE-224 trial testing in patients who were previously treated with Nexavar showed that it produced an overall response rate of 16.3% with a disease control rate of 61.5% in 104 evaluable patients; median progression-free survival (PFS) was 4.8 months with a six-month PFS rate of 43.1%; six-month OS rate was 77.9%

1/22/18

Merus NV (Utrecht, the Netherlands)

MCLA-128

Full-length IgG bispecific antibody

Metastatic breast cancer

The first patient has been dosed in a phase II trial

1/29/18

Nymox Pharmaceutical Corp. (Hasbrouck Heights, N.J.)

Fexapotide

Pro-apoptotic protein

T1c prostate cancer

Five-year results from its U.S. Study NX03-0040 showed that 15 mg single-dosage treatment resulted in 80% less surgery or radiotherapy associated with Gleason grade progression (p=0.0003), and that both doses (15 mg and 2.5 mg) were consistently effective (p=0.0003); 4.4% of patients in the entire group showed increase in their Gleason primary pattern grade in the five-year study, compared to controls where the incidence of grade 4 or higher primary pattern was 23.5%, a reduction of 81.3% (p=.0061)

1/23/18

Oncosec Medical Inc. (San Diego)

Immunopulse IL-12

DNA-based intratumoral immunotherapy

Metastatic triple-negative breast cancer

Preliminary OMS-I140 data showed two of the five patients treated with it were subsequently treated with Opdivo and experienced robust objective responses in both Immunopulse IL-12-treated and untreated lesions

1/19/18

Rasna Therapeutics Inc. (New York)

Act D

Actinomycin D

Acute myeloid leukemia

Phase II data showed that four of out nine (44%) patients carrying the NPM1 gene mutation achieved complete remission (CR); three out of the four (75%) patients who obtained CR relapsed after three, five and seven months, respectively; one patient underwent haploidentical allogeneic peripheral blood stem cell transplantation at three months after CR achievement and is alive in molecular CR (MRD-negative) after 24 months; treatment was well-tolerated, with oral mucositis as the major toxicity

1/4/18

Rexahn Pharmaceuticals Inc. (Rockville, Md.)

RX-3117

Nucleoside compound

Metastatic pancreatic cancer

Final phase IIa data showed that of the 43 patients included in the efficacy analysis, 31% had progression-free survival of at least two months while 12% of patients had disease stabilization of more than four months

1/23/18

Transgene SA (Strasbourg, France)

TG-4010

Active immunotherapy against MUC1 tumor-associated antigen

Advanced nonsquamous non-small-cell lung cancer

Dosed the first patient in a phase II trial

1/17/18

Trovagene Inc. (San Diego)

PCM-075

Selective polo-like kinase 1 inhibitor

Metastatic castration-resistant prostate cancer

Started a phase II trial

1/25/18

Tyme Technologies Inc. (New York)

SM-88

Oral, tyrosine-based therapy

Advanced metastatic or recurrent pancreatic cancer

Phase II data demonstrated prolonged survival, with 40% (four of 10) of evaluable patients surviving more than 12 months, and 30% (three of 10) achieving a complete or partial response; all 10 reduced or maintained pain scores during their first cycle of therapy, in addition to gaining or maintaining weight; 80% showed improvement in ECOG performance status during the first treatment cycle, with 30% demonstrating an improvement of greater than 1.6 during that six-week period

1/22/18

Cardiovascular

Akcea Therapeutics Inc. (Cambridge, Mass.)

AKCEA-APOCIII-LRx

Antisense drug

Hypertriglyceridemia and established cardiovascular (CV) disease

Started a phase IIb study

1/9/18

Arca Biopharma Inc. (Westminster, Colo.)

Gencaro

Bucindolol hydrochloride

Atrial fibrillation or atrial flutter

Completed patient follow-up of its phase IIb GENETIC-AF trial

1/9/18

Bellerophon Therapeutics Inc. (Warren, N.J.)

Inopulse

Pulsed, inhaled nitric oxide

Pulmonary hypertension associated with interstitial lung disease

The first patient was randomized in a phase IIb study

1/4/18

Eiger Biopharma-ceuticals Inc. (Palo Alto, Calif.)

Ubenimex

Dual-inhibitor of aminopeptidase and leukotriene A4 hydrolase

Pulmonary arterial hypertension

The phase II LIBERTY study did not meet the primary efficacy endpoint of pulmonary vascular resistance and the secondary endpoint of 6-minute walk distance; the company will discontinue development

1/17/18

Dermatologic

Xbiotech Inc. (Austin, Texas)

MABp-1

Monoclonal antibody targeting Interleukin 1alpha

Hidradenitis suppurativa

The phase II study achieved its primary endpoint, showing significant treatment benefit using the HiSCR, or Hidradenitis Suppurativa Clinical Response, endpoint

1/29/18

Endocrine/Metabolic

Caladrius Biosciences Inc. (Basking Ridge, N.J.)

CLBS-03

Autologous cell therapy

Type 1 diabetes

Completed enrollment in the phase II trial: The Sanford Project: T-Rex Study

1/19/18

Gemphire Therapeutics Inc. (Livonia, Mich.)

Gemcabene

Small molecule

Severe hypertriglyceridemia

Achieved its enrollment goal of 90 subjects in its phase IIb INDIGO-1 trial

1/18/18

Minoryx Therapeutics SL (Mataro, Spain)

MIN-102

PPAR gamma agonist

Adrenomyelo-neuropathy

Treated the first two patients in its phase II/III ADVANCE trial

1/5/18

Zafgen Inc. (Boston)

ZGN-1061

MetAP2 inhibitor

Type 2 diabetes

Completed enrollment in a phase II study

1/8/18

Gastrointestinal

Cymabay Therapeutics Inc. (Newark, Calif.)

Seladelpar

Selective PPAR-δ agonist

Primary biliary cholangitis

Enrolled the first patients in its phase II/III extension study

1/9/18

Protalix Biotherapeutics Inc. (Carmiel, Israel)

OPRX-106

Oral anti-TNF

Ulcerative colitis

Interim data from the first 14 patients who completed to date the phase II trial showed that 57% achieved clinical response and 36% achieved clinical remission at week eight; in the rectal bleeding analysis, 79% showed an improvement, with 86% of those patients achieving an improvement in calprotectin and 64% with an improved Geboes score

1/3/18

Redhill Biopharma Ltd. (Tel Aviv, Israel)

RHB-102

Bekinda

Diarrhea-predominant irritable bowel syndrome

The phase II trial met its primary endpoint with it improving stool consistency by absolute difference of 20.7% vs. placebo

1/17/18

Genitourinary/Sexual Health

Emotional Brain BV (Almere, the Netherlands)

Lybrido and Lybridos

Testosterone and sildenafil; testosterone and buspirone

Female sexual interest and arousal disorder

Phase IIb data showed Lybrido increased the satisfactory sexual events (SSEs) from baseline by 1.7 events compared to placebo and by 1.95 and 1.69 events compared to the sildenafil and testosterone monotherapies, respectively; Lybridos increased the SSEs by 0.99 events compared to placebo and by 1.52 and 0.98 events compared to the buspirone and testosterone monotherapies, respectively

1/10/18

Enteris Biopharma Inc. (Boonton, N.J.)

Ovarest

Oral formulation of leuprolide

Endometriosis

Phase IIa data showed it enabled significant suppression of estradiol (E2), demonstrating a measurable pharmacodynamic effect that is correlated with efficacy in endometriosis

1/4/18

Hansa Medical AB (Lund, Sweden)

Ides

Immunoglobulin G-degrading enzyme of Streptococcus pyogenes

Chronic kidney failure

Completed enrollment in its phase II Highdes trial

1/5/18

Hematologic

Akebia Therapeutics Inc. (Cambridge, Mass.)

Vadadustat

Oral hypoxia-inducible factor stabilizer

Anemia associated with dialysis-dependent chronic kidney disease

Phase II results are consistent with findings from previous studies

1/5/18

Beyondspring Inc. (New York)

Plinabulin

Non-granulocyte colony-stimulating factor (G-CSF) agent

Prevention of docetaxel chemotherapy-induced neutropenia (CIN)

The phase II portion of the phase II/III trial demonstrated that the duration of severe neutropenia (DSN) data for it is very similar to the DSN of Neulasta; incidence of grade 4 neutropenia was the same for Neulasta as for 20 mg/m2 plinabulin

1/29/18

Catalyst Biosciences Inc. (South San Francisco)

Marzeptacog alfa (activated)

Subcutaneously administered factor VIIa therapy

Hemophilia A or B

Initiated enrollment of the phase II part of the phase II/III program

1/5/18

Octapharma AG (Lachen, Switzerland)

Octanate

High-purity human Factor VIII / von Willebrand Factor (VWF) concentrate

Severe hemophilia A

Final data from a good clinical practice trial in previously untreated patients demonstrated that it is efficacious and associated with a low rate of inhibitor development in those patients, including those undergoing surgical procedures; five (9.8%) patients developed inhibitors, 4 (7.8%) of which were high titer; all inhibitors developed during on-demand treatment and all four high-titer inhibitors developed within the first 20 exposure days

1/23/18

Immune

Cytori Therapeutics Inc. (San Diego)

Habeo

Cell therapy

Impaired hand function due to scleroderma (systemic sclerosis)

Completed enrollment in the phase II SCLERADEC II trial

1/23/18

Eiger Biopharma-ceuticals Inc. (Palo Alto, Calif.)

Ubenimex

Inhibitor of leukotriene A4 hydrolase

Primary and secondary lymphedema of the lower limb(s)

Completed enrollment of the phase II ULTRA trial

1/5/18

Kamada Ltd. (Rehovot, Israel)

IV AAT

Intravenous alpha-1 antitrypsin

Lung transplant rejection

Phase II data showed that of the 10 patients who received IV AAT plus standard of care (SOC), four died from common transplant-related complications; two of the six patients in the SOC arm died; of the six treatment patients who lived, two experienced the acute rejections, but their situations resolved

1/10/18

Mapi Pharma Ltd. (Ness Ziona, Israel)

GA Depot, a long-acting formulation of glatiramer acetate

Long-acting formulation of glatiramer acetate

Pprimary progressive multiple sclerosis

Treated the first patient in a phase II trial

1/31/18

Oryzon Genomics SA (Madrid, Spain)

ORY-2001

Brain-penetrant drug that selectively inhibits LSD1 and MAOB

Multiple sclerosis

The first patient was included in the SATEEN phase IIa trial

1/30/18

Infection

Aclaris Therapeutics Inc. (Malvern, Pa.)

A-101

High-concentration hydrogen peroxide topical solution

Verruca vulgaris

Two phase II trials (WART-202 and WART-203) met all primary and secondary endpoints; in WART-203, where 159 patients were treated twice a week, it reduced the Physician's Wart Assessment (PWA) score on day 56 by 0.87 points compared to a reduction of 0.17 points for patients receiving placebo; in WART-202, where 157 patients were treated once weekly, it reduced the PWA score on day 56 by 0.77 points compared to a 0.23-point reduction in patients taking placebo

1/10/18

Ait Therapeutics Inc. (New York)

Nitric oxide

Inhaled version

Nontuberculous mycobacteria (NTM)

Data at day 81, the end of its phase II NO-NTM Abscessus trial, showed the Mycobacterium abscessus load had a mean reduction of 65% vs. baseline; all patients in the trial were refractory to the standard of care for NTM abscessus and had underlying cystic fibrosis

1/23/18

Chimerix Inc. (Durham, N.C.)

Brincidofovir

Nucleotide analog with antiviral activity

Adenovirus

Launched AdAPT (Adenovirus after Allogeneic Pediatric Transplantation), a comparative study designed to demonstrate the superiority of its antiviral effect in pediatric transplant recipients

1/8/18

Emergent Biosolutions Inc. (Gaithersburg, Md.)

FLU-IGIV

IV influenza immune globulin

Influenza A infection

Started a phase II dose-ranging study

1/5/18

Novan Inc. (Morrisville, N.C.)

SB-208

Topical nitric oxide-based, silicone-based gel

Fungal infections of the skin and nails

Phase II data showed that 61.3% (p = 0.209) of patients treated with 2% gel, 80.6% (p = 0.002) of patients treated with 4% gel and 74.2% (p = 0.016) of patients treated with 16% gel achieved negative fungal culture at day 14 vs. 45.5% of patients treated with vehicle; the percentage of patients achieving mycological cure at the day 14 visit was 34.4% (p=0.305) of the patients treated with the 2% gel, 50% (p=0.009) with the 4% and 53.1% (p=0.010) with the 16% dose vs. 23.5% of patients treated with vehicle

1/12/18

Novan Inc. (Morrisville, N.C.)

SB-206

Nitric oxide product

Molluscum contagiosum

Treated the first patient in a phase II trial

1/26/18

Paratek Pharmaceuticals Inc. (Boston)

Omadacycline

Antibiotic

Urinary tract infection

Started the first of two phase II trials

1/4/18

Musculoskeletal

Acceleron Pharma Inc. (Cambridge, Mass.)

ACE-083

Based on the naturally-occurring protein follistatin

Facioscapulo-humeral dystrophy

Released positive preliminary safety and tolerability data for the first two cohorts in part one of the phase II trial

1/9/18

Neuraltus Pharmaceuticals Inc. (San Bruno, Calif.)

NP-001

Regulator of macrophage activation

Amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation

All patients completed their last visit in the phase II trial

1/5/18

Orphazyme A/S (Copenhagen)

Arimoclomol

Heat shock protein-based therapy

SOD1 amyotrophic lateral sclerosis (ALS)

Phase II data showed it was safe and well-tolerated at a dosage of 200 mg three times a day for up to 12 months; secondary endpoints, including survival, function based on ALS Functional Rating Scale Revised scores, vital capacity, and the combined assessment of function and survival, all favored it although they weren't powered to demonstrate efficacy

1/26/18

Summit Therapeutics plc (Oxford, U.K.)

Ezutromid

Utrophin modulator

Duchenne muscular dystrophy

Interim phase II data showed treatment resulted in a reduction in muscle damage as measured by a 23% decrease in mean developmental myosin in muscle biopsies at 24 weeks compared to baseline (11.37% to 8.76%, 95% CI, -4.33, -0.90); 14 of 22 patients showed a decrease in developmental myosin, with five of those showing a greater than 40% reduction

1/26/18

Neurology/Psychiatric

Anavex Life Sciences Corp. (New York)

ANAVEX2-73

Agonist of the intracellular sigma-1 chaperone protein

Mild to moderate Alzheimer's disease

Post-hoc analysis of blood pressure data collected during the phase IIa study demonstrated that it seems to normalize systolic blood pressure (SBP) in a patient population with risk for hypertension; statistical analyses indicate a normalization of SBP from baseline of 143.3 mmHg to the subsequent readings after administration of 132.5 mmHg (p=0.048) at day 25 and of 135.3 mmHg (p=0.008) at day 36, respectively

1/17/18

Antibe Therapeutics Inc. (Toronto)

ATB-346

Hydrogen sulfide-releasing derivative of naproxen

Acute and chronic pain

The final subjects were enrolled in the phase IIb double-blind trial of healthy volunteers

1/30/18

Axovant Sciences Ltd. (Basel, Switzerland)

Intepirdine

5-HT6 receptor antagonist

Dementia with Lewy bodies

Discontinued development after missing its primary efficacy endpoints in the phase IIb Headway trial as well as the pilot phase II gait and balance study in patients with various types of dementia

1/9/18

Axovant Sciences Ltd. (Basel, Switzerland)

Nelotanserin

5-HT2A inverse agonist

Dementia with Lewy bodies (DLB)

Met its pre-specified primary safety endpoint of safety in the pilot phase II DLB visual-hallucination study and turned up a positive trend in efficacy in a pre-specified intent to treat (ITT) analysis of the motor function scale, the Unified Parkinson's Disease Rating Scale (UPDRS) Part III; it also showed an efficacy signal in a post-hoc subset analysis of patients with higher baseline scores on the Scale for the Assessment of Positive Symptoms in PD

1/9/18

Intelgenx Corp. (Saint-Laurent, Quebec)

Montelukast Versafilm

CysLT1 antagonist

Mild to moderate Alzheimer's disease

Started a phase IIa proof-of-concept trial

1/25/18

Neurotrope Inc. (New York)

Bryostatin

PKC epsilon activator

Advanced Alzheimer's disease

Phase II data showed evidence of improvement in cognition in patients receiving the 20 mcg regimen who did not receive memantine as background therapy; at week 15, non-memantine patients in the modified intent-to-treat group treated with 20 mcg (n=14) showed a Severe Impairment Battery (SIB) scale improvement of 5.88, while the placebo patients (n=11) showed a decline in their SIB scores of -0.05 (p=0.0576)

1/8/18

PTC Therapeutics Inc. (South Plainfield, N.J.)

RG-7916

Survival motor neuron 2 (SMN2) splicing modifier

Spinal muscular atrophy

Interim FIREFISH data showed the drug was safe and well-tolerated at all doses, and there have been no drug-related safety findings leading to withdrawal

1/30/18

Recro Pharma Inc. (Malvern, Pa.)

I.V. meloxicam

COX-2 inhibitor

Pain following dental surgery

Phase II data showed a statistically significant difference in Summed Pain Intensity Difference over the first 24 hours (SPID24) compared with placebo at each dose level, and I.V. doses of 30 mg and 60 mg both demonstrated a statistically significant difference in SPID24 compared with oral ibuprofen 400 mg; it had a favorable safety and tolerability profile, with no serious adverse events or discontinuations due to adverse events reported

1/18/18

ZZ Biotech LLC (Houston)

3K3A-APC

Genetically engineered variant of the naturally occurring activated protein C

Acute ischemic stroke

Phase II RHAPSODY data showed all doses were deemed safe and well-tolerated, yielding an maximally tolerated dose of 540 mcg/kg, the highest dose studied; total hemorrhage volume and hemorrhage incidence were substantially reduced and the incidence of any hemorrhage was reduced from 86.5% in placebo-treated patients to 67.4% in the combined treatment arms (p=0.046); total hemorrhage volume was reduced from an average of 2.1±5.8 mL on placebo to 0.8±2.1 mL in the combined treatment arms (p=0.066)

1/30/18

Ocular

Aldeyra Therapeutics Inc. (Lexington, Mass.)

ADX-102

Reproxalap

Dry eye disease

Enrolled the first patient in a phase IIb trial

1/31/18

Kalvista Pharmaceuticals Inc. (Cambridge, Mass.)

KVD-001

Intravitreally administered small-molecule plasma kallikrein inhibitor

Diabetic macular edema

Started a phase II proof-of-concept study

1/8/18

Novaliq GmbH (Heidelberg, Germany)

NOV03

Perfluorohexyloctane

Dry eye disease

Enrolled the first patients in its phase II SEECASE trial

1/9/18

Ophthotech Corp. (New York)

Zimura

Avacincaptad pegol

Autosomal recessive Stargardt disease

Enrolled the first patient in a phase IIb trial

1/17/18

Other/Miscellaneous

Innovation Pharmaceuticals Inc. (Beverly, Mass.)

Brilacidin

Defensin mimetic

Oral mucositis (OM)

Phase II trial in patients receiving chemoradiation for treatment of head and neck cancer showed a clear separation from placebo in delaying the onset of severe OM – particularly from about 28 to 42 days after the initiation of treatment, during which the incidence of severe OM rose strikingly in the placebo group while not in the group being treated; data measuring duration of severe OM showed it appeared to decrease the initial duration

1/4/18

Rhythm Pharmaceuticals Inc. (Boston)

Setmelanotide

Melanocortin-4 receptor agonist

Bardet-Biedl and Alström syndromes

A phase II study of its once-weekly formulation demonstrated tolerability and pharmacokinetics that support further clinical development

1/5/18

Saniona AB (Copenhagen)

Tesomet

Tesofensine/metoprolol

Prader-Willi syndrome

One of the three patients receiving placebo and four of the six patients who received it dropped out of the phase IIa study, preempting statistical evaluation; patients taking it lost 5% of their body weight after eight weeks compared to 0.46% for patients receiving placebo; after 13 weeks, the two remaining patients lost 6.76% of their body weight compared to 0.75% for the two patients receiving placebo

1/10/18

Respiratory

Galapagos NV (Mechelen, Belgium)

GLPG-2222

CFTR corrector

Cystic fibrosis

FLAMINGO phase II data showed it was well tolerated, with observed treatment-emergent adverse events being predominantly mild or moderate and typical; doses achieved the targeted exposure levels; a statistically significant dose-dependent decrease in sweat chloride concentration was observed with a maximum decrease of 18.3 mmol/L in the dose C cohort

1/4/18

Galapagos NV (Mechelen, Belgium)

GLPG-2737

C2 corrector

Cystic fibrosis

Dosed the first patient in the PELICAN phase II study

1/4/18


Notes

The date indicated refers to the BioWorld issue in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.